Understanding Immunopathogenesis of Tuberculosis in HIV-1 Infected and Exposed Children (R01 Clinical Trial Not Allowed)

The summary for the Understanding Immunopathogenesis of Tuberculosis in HIV-1 Infected and Exposed Children (R01 Clinical Trial Not Allowed) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Understanding Immunopathogenesis of Tuberculosis in HIV-1 Infected and Exposed Children (R01 Clinical Trial Not Allowed): The purpose of this Funding Opportunity Announcement (FOA) is to encourage research applications to identify changes in immune mechanisms and markers because of Mycobacterium tuberculosis (Mtb) exposure, infection or disease in pediatric populations exposed to or infected with HIV-1.

Federal Grant Title:	Understanding Immunopathogenesis of Tuberculosis in HIV-1 Infected and Exposed Children (R01 Clinical Trial Not Allowed)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-AI-17-039
Type of Funding:	Grant
CFDA Numbers:	93.855
CFDA Descriptions:	Information not provided
Current Application Deadline:	March 14th, 2018
Original Application Deadline:	March 14th, 2018
Posted Date:	December 4th, 2017
Creation Date:	December 4th, 2017
Archive Date:	April 19th, 2018
Total Program Funding:	$3,800,000
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	December 4th, 2017

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-17-039.html
Grant Announcement Contact: NIH OER Webmaster
[email protected]

If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Strategies for Eliminating HIV Proteins (R21 Clinical Trial Not Allowed); • Strategies for Eliminating HIV Proteins (R01 Clinical Trial Not Allowed); • Promoting Innovative Research in Treponema pallidum Pathogenesis (R21 Clinical Trial Not A...; • Novel Approaches for Radiation Biodosimetry and Medical Countermeasure Development (R21 Cl...; • Halting Tuberculosis (TB) Transmission (R01 Clinical Trial Optional); • Center for HIV/AIDS Vaccine Immunology (CHAVI); • Genomics of Transplantation Cooperative Research Program; • Asthma and Allergic Diseases Cooperative Research Centers
More Grants from the National Institutes of Health: • Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed...; • Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional); • NIA Advanced Postdoctoral Career Transition Awards to Promote Diversity in Translational R...; • Clinical and Translational Science Award (UM1 Clinical Trial Optional); • Tribal Undergraduate to Graduate Research Training and Leadership Experiences (TURTLE) Pro...